138 related articles for article (PubMed ID: 38630325)
21. Discovery of potential HER2 inhibitors from
Balogun TA; Iqbal MN; Saibu OA; Akintubosun MO; Lateef OM; Nneka UC; Abdullateef OT; Omoboyowa DA
J Biomol Struct Dyn; 2022; 40(23):12772-12784. PubMed ID: 34514973
[TBL] [Abstract][Full Text] [Related]
22.
Rajagopal K; Kalusalingam A; Bharathidasan AR; Sivaprakash A; Shanmugam K; Sundaramoorthy M; Byran G
Molecules; 2023 May; 28(10):. PubMed ID: 37241915
[TBL] [Abstract][Full Text] [Related]
23. Computational investigation of
Yousaf MA; Anwer SA; Basheera S; Sivanandan S
J Biomol Struct Dyn; 2024; 42(4):1901-1923. PubMed ID: 37154824
[TBL] [Abstract][Full Text] [Related]
24. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
25. Identification of potential inhibitors of HER2 targeting breast cancer-a structure-based drug design approach.
Singh G; Al-Fahad D; Al-Zrkani MK; Chaudhuri TK; Soni H; Tandon S; Narasimhaji CV; Azam F; Patil R
J Biomol Struct Dyn; 2023 Aug; ():1-18. PubMed ID: 37565730
[TBL] [Abstract][Full Text] [Related]
26. Dual functionality of pyrimidine and flavone in targeting genomic variants of EGFR and ER receptors to influence the differential survival rates in breast cancer patients.
Avti PK; Singh J; Dahiya D; Khanduja KL
Integr Biol (Camb); 2023 Apr; 15():. PubMed ID: 38084900
[TBL] [Abstract][Full Text] [Related]
27. Investigation of the New Inhibitors by Sulfadiazine and Modified Derivatives of α-D-glucopyranoside for White Spot Syndrome Virus Disease of Shrimp by In Silico: Quantum Calculations, Molecular Docking, ADMET and Molecular Dynamics Study.
Kumer A; Chakma U; Rana MM; Chandro A; Akash S; Elseehy MM; Albogami S; El-Shehawi AM
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744817
[TBL] [Abstract][Full Text] [Related]
28. Integrative analysis discovers Imidurea as dual multitargeted inhibitor of CD69, CD40, SHP2, lysozyme, GATA3, cCBL, and S-cysteinase from SARS-CoV-2 and M. tuberculosis.
Ahmad S; Singh AP; Bano N; Raza K; Singh J; Medigeshi GR; Pandey R; Gautam HK
Int J Biol Macromol; 2024 May; 270(Pt 2):132332. PubMed ID: 38768914
[TBL] [Abstract][Full Text] [Related]
29. In Silico Targeting Human Multidrug Transporter ABCG2 in Breast Cancer: Database Screening, Molecular Docking, and Molecular Dynamics Study.
Ibrahim MAA; Badr EAA; Abdelrahman AHM; Almansour NM; Mekhemer GAH; Shawky AM; Moustafa MF; Atia MAM
Mol Inform; 2022 Feb; 41(2):e2060039. PubMed ID: 34491628
[TBL] [Abstract][Full Text] [Related]
30. Exploring the potential of approved drugs for triple-negative breast cancer treatment by targeting casein kinase 2: Insights from computational studies.
Shoaib TH; Ibraheem W; Abdelrahman M; Osman W; Sherif AE; Ashour A; Ibrahim SRM; Ghazawi KF; Miski SF; Almadani SA; ALsiyud DF; Mohamed GA; Alzain AA
PLoS One; 2023; 18(8):e0289887. PubMed ID: 37578958
[TBL] [Abstract][Full Text] [Related]
31. Identification of HER2 inhibitors from curcumin derivatives using combination of
Saibu OA; Singh G; Olugbodi SA; Oluwafemi AT; Ajayi TM; Hammed SO; Oladipo OO; Odunitan TT; Omoboyowa DA
J Biomol Struct Dyn; 2023; 41(21):12328-12337. PubMed ID: 36752338
[TBL] [Abstract][Full Text] [Related]
32. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
[TBL] [Abstract][Full Text] [Related]
33. Natural Phytocompounds from Common Indian Spices for Identification of Three Potential Inhibitors of Breast Cancer: A Molecular Modelling Approach.
Hazra S; Ray AS; Rahaman CH
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235128
[TBL] [Abstract][Full Text] [Related]
34. Molecular docking, ADMET and molecular dynamics simulation revealed metralindole as a multitargeted inhibitor for division kinases.
Al-Dhuayan I; ALaqeel NK
Braz J Biol; 2023; 83():e271688. PubMed ID: 37075433
[TBL] [Abstract][Full Text] [Related]
35. Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches.
Rampogu S; Son M; Baek A; Park C; Rana RM; Zeb A; Parameswaran S; Lee KW
Comput Biol Chem; 2018 Jun; 74():327-338. PubMed ID: 29702367
[TBL] [Abstract][Full Text] [Related]
36. Atomic level and structural understanding of natural ligands inhibiting
Sunder Raj D; Kesavan DK; Kottaisamy CPD; Kumar VP; Hopper W; Sankaran U
J Biomol Struct Dyn; 2023 May; 41(8):3440-3461. PubMed ID: 35293845
[No Abstract] [Full Text] [Related]
37. A drug design strategy based on molecular docking and molecular dynamics simulations applied to development of inhibitor against triple-negative breast cancer by Scutellarein derivatives.
Akash S; Aovi FI; Azad MAK; Kumer A; Chakma U; Islam MR; Mukerjee N; Rahman MM; Bayıl I; Rashid S; Sharma R
PLoS One; 2023; 18(10):e0283271. PubMed ID: 37824496
[TBL] [Abstract][Full Text] [Related]
38. In-silico analysis reveals Quinic acid as a multitargeted inhibitor against Cervical Cancer.
Ahmad S; Sayeed S; Bano N; Sheikh K; Raza K
J Biomol Struct Dyn; 2023 Nov; 41(19):9770-9786. PubMed ID: 36379678
[TBL] [Abstract][Full Text] [Related]
39. Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents.
Ahmed MZ; Zia Q; Haque A; Alqahtani AS; Almarfadi OM; Banawas S; Alqahtani MS; Ameta KL; Haque S
J Infect Public Health; 2021 May; 14(5):611-619. PubMed ID: 33866129
[TBL] [Abstract][Full Text] [Related]
40. Investigating the multitargeted anti-diabetic potential of cucurbitane-type triterpenoid from
Famuyiwa SO; Ahmad S; Olufolabo KO; Olanudun EA; Bano N; Oguntimehin SA; Adesida SA; Oyelekan EI; Raza K; Faloye KO
J Biomol Struct Dyn; 2023 Dec; ():1-12. PubMed ID: 38069604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
